Balancing the cost of innovation and ensuring access to high-quality, effective medical treatment continues to be a challenge for all modern healthcare systems. Significant shifts in global and local market dynamics, policy and politics are prompting a discussion about other dimensions of value, be they economic, social, or scientific. How can biotech innovators best demonstrate the value of their therapies so that outcomes are measurable and relevant to all stakeholders?
Moderator: Joseph Damond – Biotechnology Innovation Organization (BIO)
- Kate Bingham – SV Life Sciences Advisers
- Jörg Möller – Bayer AG
- Rehan Verjee – Merck KGaA
- Juergen Windeler – Institute for Quality and Efficiency in Health Care, IQWiG